Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More

Invitrogen™ Human FGD4 (aa 120-205) Control Fragment Recombinant Protein

Catalog No. RP97793
Encompass_Preferred
Change view
Click to view available options
Quantity:
100 μL
1 product options available for selection
Product selection table with 1 available options. Use arrow keys to navigate and Enter or Space to select.
Catalog No. Quantity
RP97793 100 μL
Use arrow keys to navigate between rows. Press Enter or Space to select a product option. 1 options available.
1 options
Catalog No. RP97793 Supplier Invitrogen™ Supplier No. RP97793
  • $283.00
    $212.25 / Each of 1

    Save $70.75

    25% Off The following deviations and disclosures may produce prices below stated discounts but will not trigger price reductions: Price shown reflects a temporary, promotional price reduction. No other purchase or commercial obligation required to receive the reduced price. Price may change at any time. Promotional price valid on web orders only. Your contract pricing may differ. Other exclusions apply.
Add to Cart
Add to Cart

Recombinant Protein

Highest antigen sequence indentity to the following orthologs: Mouse (53%), Rat (53%). This recombinant protein control fragment may be used for blocking experiments with the corresponding antibody, PA5-58706. In IHC/ICC and WB experiments, we recommend a 100x molar excess of the protein fragment control based on the concentration and the molecular weight. Pre-incubate the antibody-protein control fragment mixture for 30 min at room temperature.

The FGD4 gene, also known as FYVE, RhoGEF, and PH domain-containing protein 4, is located on chromosome 12p11.21. This gene encodes a protein involved in the regulation of the actin cytoskeleton and is crucial for cellular processes such as migration and adhesion. FGD4 is specifically associated with Charcot-Marie-Tooth disease type 4H (CMT4H), a rare autosomal recessive hereditary neuropathy characterized by early onset, progressive distal muscle weakness, scoliosis, and myelin outfoldings. Mutations in FGD4 result in disruptions of its function, leading to the clinical manifestations of CMT4H. Additionally, the gene has been implicated in cancer biology, with its expression correlating with aggressive phenotypes in some cancers and contributing to therapeutic resistances. The gene includes multiple exons and alternative splicing variants, underlining its broad functional implications.
TRUSTED_SUSTAINABILITY

Specifications

Accession Number Q96M96
Concentration ≥5.0 mg/mL
For Use With (Application) Neutralization, Control
Formulation PBS, 1M urea with no preservative; pH 7.4
Gene ID (Entrez) 121512
Name Human FGD4 (aa 120-205) Control Fragment
pH Range 7.4
Purification Method Purified
Quantity 100 μL
Storage Requirements -20°C, Avoid Freeze/Thaw Cycles
Regulatory Status RUO
Gene Alias Actin filament-binding protein frabin; actin-filament binding protein frabin; CMT4H; FGD1 family, member 4; FGD1-related F-actin-binding protein; FGD4; FRABP; FYVE, RhoGEF and PH domain containing 4; FYVE, RhoGEF and PH domain-containing protein 4; ZFYVE6; Zinc finger FYVE domain-containing protein 6
Common Name FGD4
Gene Symbol FGD4
Product Type Protein
Conjugate Unconjugated
Species Human
Recombinant Recombinant
Protein Tag His-ABP-tag
Sequence EPLLDTHIVNGERDETATAPASPTTDSCDGNASDSSYRTPGIGPVLPLEERGAETETKVQERENGESPLELEQLDQHHEMKETNEQ
Content And Storage -20°C, Avoid Freeze/Thaw Cycles
Expression System E. coli
Form Liquid
Purity or Quality Grade >80% by SDS-PAGE and Coomassie blue staining
Show More Show Less
Product Title
Select an issue

By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.